PP
SCLN

PDT Partners’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

PDT Partners’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-49,629
Closed -$509K – 579
2016
Q3 		$509K Buy
49,629
+2,400
+5% +$26.1K 0.03% 373
2016
Q2 		$617K Hold
47,229
– – 0.05% 311
2016
Q1 		$520K Hold
47,229
– – 0.03% 409
2015
Q4 		$435K Sell
47,229
-259,408
-85% -$2.17M 0.06% 287
2015
Q3 		$2.13M Buy
306,637
+57,037
+23% +$488K 0.05% 410
2015
Q2 		$2.45M Sell
249,600
-29,401
-11% -$268K 0.06% 359
2015
Q1 		$2.47M Buy
279,001
+47,601
+21% +$379K 0.06% 396
2014
Q4 		$2.03M Buy
231,400
+14,800
+7% +$120K 0.19% 115
2014
Q3 		$1.49M Hold
216,600
– – 0.04% 513
2014
Q2 		$1.14M Hold
216,600
– – 0.03% 653
2014
Q1 		$986K Sell
216,600
-200
-0.1% -$966 0.02% 682
2013
Q4 		$1.09M Buy
216,800
+4,700
+2% +$22.6K 0.13% 223
2013
Q3 		$1.07M Buy
212,100
+7,400
+4% +$41.2K 0.03% 745
2013
Q2 		$1.01M Buy
+204,700
New +$974K 0.02% 810

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

PDT Partners's SCLN Position: Q4 2016 in Review

PDT Partners sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 49,629 shares — an estimated $509K sold.

PDT Partners first reported a position in SCLN in Q2 2013 and held it in 14 quarters. The position peaked at $2.47M in Q1 2015. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • PDT Partners reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • PDT Partners sold 49,629 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $509K.
  • PDT Partners first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 14 quarters.
  • PDT Partners's Sciclone Pharmaceuticals Inc position peaked at $2.47M in Q1 2015.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on PDT Partners's 13F filing for Q4 2016, filed 14 Feb 2017.